March 31, 2016
4 min read
Save

Prolonged nightly fasting may reduce breast cancer recurrence risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Fasting for fewer than 13 hours per night may increase the risk for disease recurrence in women with early-stage breast cancer, according to an analysis of data from the Women’s Health Eating and Living study.

Perspective from Douglas Yee, MD

Although previous studies on nightly fasting duration and clinical outcomes have not been conducted, research suggests fasting regimens can improve breast cancer risk factors related to glucoregulation, inflammation, obesity and sleep.

Ruth Patterson

Ruth E. Patterson

Ruth E. Patterson, PhD, professor in the department of family medicine and public health at University of California, San Diego, and associate director of population sciences and leader of the cancer prevention program at the Moores Cancer Center, and colleagues used data from the Women’s Health Eating and Living study to evaluate whether nightly fasting duration was associated with breast cancer recurrence and mortality.

The Women’s Health Eating and Living study — conducted between 1995 and 2007 — included women who recently had early-stage breast cancer. Researchers of that trial sought to assess whether a diet rich in vegetables, fruit and fiber and low in fat would improve breast cancer outcomes; however, the dietary intervention did not improve breast cancer prognosis after a median of 7.3 years of follow-up.

Patterson and colleagues evaluated data from 2,413 women (mean age, 52.4 years; mean BMI, 27) enrolled in this study. All women had breast cancer but did not have diabetes, and they had time-stamped, 24-hour dietary recall data and complete data on key confounders. A majority of women were white (85.5%) and college educated (55.3%).

The mean nightly fasting duration in the cohort was 12.5 hours, and women had a mean of 4.4 eating episodes daily. Overall, 1,595 of the women reported a nightly fasting duration that was shorter than 13 hours, whereas 818 of the women fasted for 13 hours or longer.

Women with a nightly fasting duration shorter than 13 hours were more likely to be college educated (57.6% vs. 50.9%; P .001), had a lower mean BMI (26.7 vs. 27.5; P .01), slept for fewer hours each night (fewer than 6 hours; 6.8% vs. 4.9%; P .001), ate more calories daily (mean, 1,769 vs. 1,644; P .001) and were more likely to eat after 8 p.m. (45.1% vs. 8.4%; P .001).

Results of repeated-measures Cox proportional hazards regression models showed fasting fewer than 13 hours nightly increased risk for breast cancer recurrence 36% compared with fasting 13 hours or more nightly (HR = 1.36; 95% CI, 1.05-1.76).

However, shorter nightly fasting did not increase risk for breast cancer-specific mortality (HR = 1.21; 95% CI, 0.91-1.6) or all-cause mortality (HR = 1.22; 95% CI, 0.95-1.56).

Each 2-hour increase in nightly fasting duration was associated with a 0.37-mmol/mol lower glycated hemoglobin level (beta = –0.37; 95% CI, –0.72 to –0.01) and more hours of sleep per night (beta = 0.2; 95% CI, 0.14-0.26).

“Given the associations of nightly fasting with glycemic control and sleep, we hypothesize that interventions to prolong the nightly fasting interval could potentially reduce the risk for type 2 diabetes, cardiovascular disease and other cancers,” Patterson and colleagues wrote. “Thus, findings from this study have broad and significant implications for public health.”

Additional trials are needed to further assess this association, according to the researchers.

“If future trials confirm that habitual prolonged nightly fasting improves metabolic health, this would be an important discovery in prevention that could reduce the risk for cancers, type 2 diabetes and cardiovascular disease,” Patterson said in a press release. – by Alexandra Todak

Disclosure : The researchers report no relevant financial disclosures.